Omega Healthcare Investors Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +3.54%.
Did OHI Beat Earnings? Q2 2025 Results
Omega Healthcare Investors delivered a standout second quarter, with earnings per share of $0.46 beating the $0.41 consensus estimate by 12.11% and revenue of $282.51 million clearing Wall Street expectations by 16.12% while climbing 11.8% year over year. The primary engine behind those results was an aggressive $527 million deployment of capital during the quarter, anchored by a $344.20 million acquisition of 45 facilities across the U.K. and the Bailiwick of Jersey, which drove rental income to $235.60 million from $210.40 million a year ago. Adjusted FFO reached $232.22 million, or $0.77 per diluted share, compared to $0.71 per share in Q2 2024, reflecting the portfolio's expanded earnings base. Executives pointed to improving operator occupancy of 82.2% and EBITDARM coverage rising to 1.88x as evidence of continued recovery in the skilled nursing sector, even as Genesis Healthcare's Chapter 11 filing added a note of caution. Omega raised its full-year 2025 AFFO guidance to $3.04 to $3.07 per share, up from the prior $2.95 to $3.01 range, underpinned by $605 million in year-to-date investments.
- Rental income growth to $235.6 million from $210.4 million in Q2 2024
- Approximately $527 million in new Q2 investments including $502 million in real estate acquisitions
- Improved operator occupancy to 82.2% with EBITDARM coverage of 1.88x
- Growing FAD per share to $0.74 from $0.68 in Q2 2024
- U.K. portfolio expansion with 45-facility acquisition for approximately $344 million
- Maplewood rent increase to $17.6 million from $15.6 million in Q1
“We are pleased with our second quarter results, as we continue to grow FAD per share while further de-levering the balance sheet. We have accretively invested approximately $605 million year-to-date and, as a result, we are increasing our 2025 AFFO guidance again to now be between $3.04 and $3.07 per share, up from our prior guidance range of between $2.95 and $3.01 per share.”
Omega Healthcare Investors CEO, on the earnings call
Forward Guidance & Outlook
Omega increased its full-year 2025 AFFO guidance to $3.04–$3.07 per diluted share, up from the prior range of $2.95–$3.01 per share. The revised guidance incorporates $605 million in new real property and loan investments completed year-to-date through June 2025. Key assumptions include quarterly G&A expense of approximately $13.5–$14.5 million, repayment of $600 million of 5.250% senior notes due January 2026 on October 15, 2025, repayment of a $251.6 million GBP-denominated secured mortgage loan on November 25, 2025, no material changes in market interest rates, Genesis and Avardis continuing to pay full contractual obligations, Maplewood continuing to pay rent at $6.1 million per month, approximately $50 million in asset sales, and no additional acquisitions. The guidance excludes additional acquisitions, certain revenue/expense items, interest refinancing expenses, acquisition costs, capital markets activity, and additional provisions for credit losses.
OHI YoY Financials
OHI Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.